Brought to you by 
Xynomic takes on abexinostat rights from undisclosed partner
15 Mar 2017
Executive Summary
Xynomic Pharmaceuticals Inc. (oncology) licensed exclusive global rights from an undisclosed partner to develop, manufacture, and sell the HDAC inhibitor abexinostat.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xynomic takes on abexinostat rights from undisclosed partner
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice